Microbial manipulation as primary therapy for Crohn's disease.

about

Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.The role of Klebsiella in Crohn's disease with a potential for the use of antimicrobial measures Rifaximin and Crohn's disease.

P2860

Q35933419-5604D94E-B629-4235-8FEA-7CCEE37562CB Q37260906-5D805786-5522-42EA-9C63-04F778F28368 Q42883532-7B8E2C87-53B6-4689-A385-9EBD120AA7BB

P2860

Microbial manipulation as primary therapy for Crohn's disease.

Item

http://www.wikidata.org/entity/Q43224619

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Microbial manipulation as primary therapy for Crohn's disease.

@en

Microbial manipulation as primary therapy for Crohn's disease.

@nl

type

Item

label

Microbial manipulation as primary therapy for Crohn's disease.

@en

Microbial manipulation as primary therapy for Crohn's disease.

@nl

prefLabel

Microbial manipulation as primary therapy for Crohn's disease.

@en

Microbial manipulation as primary therapy for Crohn's disease.

@nl

P1476

Microbial manipulation as primary therapy for Crohn's disease.

@en

P2093

Arun Swaminath

http://www.w3.org/2001/XMLSchema#string

Randy S Longman

http://www.w3.org/2001/XMLSchema#string

P2860

Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum

Multidrug Resistance Is Common in Escherichia coli Associated with Ileal Crohnʼs Disease

Microbial exposure during early life has persistent effects on natural killer T cell function

Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease

Induction of colonic regulatory T cells by indigenous Clostridium species

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases

Double blind, placebo controlled trial of metronidazole in Crohn's disease.

P304

1513-1516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3748/WJG.V19.I10.1513

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236090959

http://www.w3.org/2001/XMLSchema#string

P698

23539531

http://www.w3.org/2001/XMLSchema#string

P932

3602467

http://www.w3.org/2001/XMLSchema#string

Microbial manipulation as primary therapy for Crohn's disease.

about

P2860

P2860

Microbial manipulation as primary therapy for Crohn's disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932